Anokion Announces Clinical Progress with KAN-101 and ANK-700
Wednesday, September 13, 2023
Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today reported progress for its clinical-stage programs, KAN-101 and ANK-700. The company’s lead product candidate, KAN-101, is being evaluated for the treatment of celiac disease, and its second candidate, ANK-700, is being evaluated for the treatment of multiple sclerosis (MS).
“2023 has been a year of significant progress for Anokion, marked by the execution of our two clinical-stage programs, KAN-101 and ANK-700, and clinical data that validate our approach to re-educating critical immune pathways in the body using durable, disease-modifying medicines,” said Deborah Geraghty, Ph.D., chief executive officer. “Based on the strength of the Phase 1 clinical data with KAN-101, the first agent to modulate gluten induced IL-2, an established biomarker associated with symptomatic responses to gluten exposure in celiac disease, we are excited to begin the first of two global Phase 2 trials after establishing additional safety at higher doses in Phase 1b earlier this year. We anticipate this trial, with the second Phase 2a histology study, will further establish clinical proof-of-concept of KAN-101 as a treatment for celiac disease, an indication with no approved therapeutic options today.”
Dr. Geraghty continued, “In parallel, we’ve completed enrollment in our MoveS-it trial assessing ANK-700 for MS, which not only further confirms the safety of the Anokion platform, but demonstrates antigen-specific trends in tolerance and bystander suppression, a highly sought after mechanism for treating complex autoimmune diseases like MS. I am incredibly proud of the accomplishments of this team and look forward to advancing both KAN-101 and ANK-700 as potential first-in-class treatments.”
About Anokion
Anokion SA is a clinical-stage Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring normal immune tolerance. The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis, and type 1 diabetes. Anokion’s distinct approach leverages the company’s immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the underlying cause of autoimmune disease. For more information, please visit anokion.com.
CONTACT
Monique Allaire
THRUST Strategic Communications
monique@thrustsc.com
